Fatty liver study tests Insulin-Lowering drug to uncover disease roots
NCT ID NCT05729282
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a drug called diazoxide, which lowers high insulin levels, can help researchers understand how fatty liver disease develops. Twenty-four adults with overweight or obesity and insulin resistance took either a low or high dose of diazoxide or a placebo for two weeks. Researchers measured changes in blood sugar, insulin, and fat levels to see how reducing insulin affects the liver's handling of sugar and fat.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INSULIN RESISTANCE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Irving Medical Center
New York, New York, 10032, United States